Women across the nation have connected online over their unexpected pregnancies, known as "Ozempic babies," while using GLP-1 ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

MariTide, a new drug from Amgen, helped some people with obesity lose up to 20% of their body weight. In a phase 2 trial, a new GLP-1 drug helped people lose up to 20% of their body weight over a year ...

In a follow-up TikTok post on March 31, O'Donnell gave another shoutout to Mounjaro for its impact on her weight loss while reflecting on the financial limitations of the drug's accessibility.

Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating ...

In the coming years, experts anticipate the approval of a variety of newer GLP-1 drugs that will boast real improvements over semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound ...